All In Biotech

Drug Trial Radar · NCT07335536

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieva

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Oct 20, 2025

Primary completion

Sep 1, 2026

Study completion Oct 1, 2026

Sponsor

Lead sponsor
Diansan SuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.

Conditions

  • Hypoxia
  • Infertility
  • Infertility Assisted Reproductive Technology

Interventions

  • remimazolam-alfentanil combinationDrug

    Administer 7 μg/kg of alfentanyl first,then given remimazolam 0.2 mg/kg (1-minute bolus), followed by 1 mg/kg/h infusion.

  • propofol-alfentanilDrug

    Administer 7 μg/kg of fentanyl first,then given propofol 2 mg/kg (1-minute bolus), followed by 6 mg/kg/h infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of HypoxiaTime frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Dongyang People's Hospital

    Dongyang, Zhejiang, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.